3SBio (HK:1530) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
3SBio Inc.’s subsidiary, Shenyang Sunshine Pharmaceutical, has secured exclusive commercialization rights for clifutinib besylate in Mainland China through a collaboration with Sunshine Lake Pharma. The agreement involves initial and milestone payments, while Sunshine Lake Pharma will manage the drug’s research, development, and production. Investors are advised to remain cautious regarding the potential success of clifutinib’s commercialization.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.
